key: cord-0849281-vzjh3hoh authors: Anand, Priyanka; Mayfield, Jacob J.; He, Beixin; Khaira, Kavita B. title: Unusual T-wave Changes and Extreme QTc Prolongation in a 71-year-old man with Asymptomatic COVID Infection date: 2021-11-17 journal: HeartRhythm Case Rep DOI: 10.1016/j.hrcr.2021.11.008 sha: 0d144083037add49d0ed9b12b13d98b3a9aed6aa doc_id: 849281 cord_uid: vzjh3hoh nan The QT interval represents the time between onset of ventricular depolarization (QRS complex) and conclusion of repolarization (terminal T wave), as detected by surface electrocardiogram (ECG). A prolonged corrected QT interval (QTc) is associated with increased risk of torsades de pointes (TdP), which can lead to ventricular fibrillation and sudden cardiac arrest. Several processes can result in prolonged QT interval, including congenital long QT syndrome, drug-mediated effects, metabolic abnormalities, and structural or electrical heart disease 1 . have been reported. However, most of these patients had severe COVID-19 infection. Below we report a unique case of severe QT prolongation and T-wave inversions in an asymptomatic patient with COVID-19. A 71-year-old man with a history of coronary artery disease (CAD) with prior coronary artery bypass grafting, stroke, and peripheral artery disease presented to the hospital with one day of lightheadedness and intermittent diplopia. Vital signs were notable for temperature of 37.5 degrees Celsius, blood pressure of 108/74 mmHg, and oxygen saturation of 98% breathing ambient air. Physical exam was notable for normal cardiopulmonary findings and euvolemia. angiography of the head and neck obtained due to concern for stroke showed no evidence of acute intracranial processes but did reveal patchy ground glass opacities within the bilateral lung apices, concerning for an infectious or inflammatory process. The patient was admitted to the hospital with hypoglycemia related to suspected sulfonylurea overdose, as he was taking Glimeperide 8mg daily. His hypoglycemia resolved within the first two days of admission. However, subsequent ECGs showed persistent deep T-wave inversions and progressive QTc prolongation, with a peak QTc of 720 msec on hospital day 7 ( Figure 1C ). Supplemental magnesium was administered. His electrolytes remained within normal ranges throughout his hospital stay. The patient consistently denied chest pain, shortness of breath, palpitations, or any symptoms attributable to COVID-19. He denied any known family history of long QT syndrome, sudden unexplained death or sudden cardiac arrest. Repeat serum troponin T assays remained undetectable. Erythrocyte sedimentation rate and C-reactive protein were mildly Transthoracic echocardiogram showed a normal left ventricular ejection fraction and no regional wall motional abnormalities, however global longitudinal strain was reduced at -14.7%. Cardiac magnetic resonance imaging (MRI) was unfortunately non-diagnostic due to motion artifact. An extended toxicology screen was sent to identify possible surreptitious use of QTprolonging agents and was negative. Genetic testing was also sent to assess for the presence of J o u r n a l P r e -p r o o f treatment for viral myocarditis due to COVID-19 was discussed but was not pursued given limited biochemical and radiological evidence of myocarditis and overall clinical stability. The patient was eventually discharged on hospital day 15 with a QTc of 568 msec. He was provided with a wearable external cardioverter defibrillator and plan for close follow up in cardiology clinic. Monthly follow up ECGs showed gradual improvement in QT prolongation, with ECG 4 months after discharge showing a QTc of 488 msec ( Figure 1D ). Several infectious and inflammatory conditions have been noted to cause QT prolongation. In a study of patients with acute infection, inflammatory makers such as CRP, IL-6 and IL-1 correlated with QT prolongation, and QT intervals improved with normalization of these markers 2 . High levels of circulating cytokines, specifically IL-6, TNF-a and IL-1, have been shown to affect cardiac Ca 2+ and K + currents in animals and in vitro studies 2 . Additionally, IL-6 has been shown to block Ikr and reduce expression of the human ether a-go-go related gene (hERG) potassium channel, akin to the mechanism of drug-induced QT prolongation 3 . Additionally, IL-1 and CRP levels have been linked to reduced mRNA expression of cardiac K + ion channels in patients with acute infection 3 . COVID-19 also appears to be associated with prolonged QT and increased risk of arrythmia, an unsurprising finding given the cytokine storm associated with severe disease. A study of 1258 patients diagnosed with COVID-19 noted prolonged QT (QTc >500 msec or >550 msec for QRS>120 msec) in 5% of patients 4 Historically, concern for QT prolongation in patients with COVID-19 has been related to the use of therapeutic agents known to prolong QT interval, such as hydroxychloroquine and azithromycin 9 . Myocardial inflammation can be a trigger for ECG changes and arrythmias in patients with COVID-19, however in many cases there is no evidence of myocardial injury 10 . Other suggested mechanisms for these electrophysiologic findings include microvascular injury due to the endothelial effects of the virus 6 , or myocardial inflammation and ion channel changes in the setting of systemic viral infection 10, 11 . It is also notable that our patient was hypoglycemic on presentation, related to glimepiride use. Severe hypoglycemia has been associated with serious arrythmias and sudden cardiac arrest 12 , and glyburide has been linked to QT prolongation 13 . However, this effect has not been observed with other agents such as glimepiride 13 . Additionally in our case, the patient's QT prolongation worsened over the course of his hospital stay, peaking on hospital day 7, well after normalization of his blood sugar and metabolic clearance of glimepiride. To our knowledge, this is the first reported case of dramatic QT prolongation and T-wave inversions in an asymptomatic patient with SARS-CoV2 without evidence of myocardial injury. While QT prolongation in COVID-19 has generally attributed to elevated cytokine levels and myocardial ischemia, the presence of severe QT prolongation in this asymptomatic patient suggests that the SARS-CoV2 virus itself may have intrinsic effects on cardiac repolarization. This case suggests that significant electrophysiologic cardiac complications of SARS-CoV2 infection can rarely occur even in asymptomatic individuals, who represent a significant portion of those with COVID-19, and may explain some of the increase in out of hospital cardiac arrest during the pandemic. High-risk individuals, including those with baseline prolonged QT interval and cardiac comorbidities, who contract SARS-CoV2 may still be at risk of developing ECG abnormalities and arrythmias, even in the absence of overt COVID-19 symptoms. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes Cardiac arrest risk during acute infections: Systemic inflammation directly prolongs QTc interval via cytokine-mediated effects on potassium channel expression Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation The prognostic value of electrocardiogram at presentation to emergency department in patients with COVID-19 T-wave inversion as a manifestation of COVID-19 infection: A case series Surface electrocardiographic characteristics in coronavirus disease 2019: Repolarization abnormalities associated with cardiac involvement. ESC heart failure COVID-19 and QT interval prolongation: More than just drug toxicity? EP Europace Prolonged QT interval in a patient with coronavirus disease-2019: Beyond hydroxychloroquine and azithromycin Considerations for drug interactions on QTc in exploratory COVID-19 treatment COVID-19, arrhythmic risk, and inflammation: Mind the gap! Circulation Systemic inflammation as a novel QTprolonging risk factor in patients with torsades de pointes Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: Silent hypoglycemias and silent arrhythmias Pro-and antiarrhythmic actions of sulfonylureas: Mechanistic and clinical evidence QT prolongation may complicate COVID-19 Clinicians should consider the risk of severe QT prolongation in patients with baseline elevated QTc and cardiac comorbidities who contract COVID-19 Given the predisposition to arrhythmia in patients COVID-19 and other systemic inflammatory states, care should be taken to avoid additional QT prolonging medications where possible